Physicians

Lunit and Summit to evaluate pathology platform for tumour analysis
- Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.







